U.S. markets open in 5 hours 49 minutes
  • S&P Futures

    3,836.00
    +8.00 (+0.21%)
     
  • Dow Futures

    31,358.00
    -13.00 (-0.04%)
     
  • Nasdaq Futures

    12,871.50
    +39.75 (+0.31%)
     
  • Russell 2000 Futures

    2,192.70
    -7.30 (-0.33%)
     
  • Crude Oil

    62.95
    -0.58 (-0.91%)
     
  • Gold

    1,759.80
    -15.60 (-0.88%)
     
  • Silver

    26.92
    -0.76 (-2.75%)
     
  • EUR/USD

    1.2157
    -0.0030 (-0.24%)
     
  • 10-Yr Bond

    1.5180
    0.0000 (0.00%)
     
  • Vix

    28.05
    +6.71 (+31.44%)
     
  • GBP/USD

    1.3953
    -0.0060 (-0.43%)
     
  • USD/JPY

    106.0530
    -0.1770 (-0.17%)
     
  • BTC-USD

    45,778.79
    -4,708.59 (-9.33%)
     
  • CMC Crypto 200

    914.64
    -18.50 (-1.98%)
     
  • FTSE 100

    6,624.71
    -27.25 (-0.41%)
     
  • Nikkei 225

    28,966.01
    -1,202.26 (-3.99%)
     

Atea Pharmaceuticals (AVIR) Jumps: Stock Rises 9.5%

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
Zacks Equity Research
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Atea Pharmaceuticals, Inc. AVIR was a big mover last session, as the company saw its shares rise more than 9% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $27.77–$34.44 in the past one-month time frame, witnessed a sharp increase on Friday.

The company has seen no change in estimates when it comes to estimate revision over the past few weeks, while the Zacks Consensus Estimate for the current quarter hasn’t been in a trend either. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Atea Pharmaceuticals currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.

A better-ranked stock in the Medical - Biomedical and Genetics industry is Repligen Corporation RGEN, which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Repligen Corporation (RGEN) : Free Stock Analysis Report
 
Atea Pharmaceuticals, Inc. (AVIR) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research